Alvotech再次向FDA提交强生Simponi和再生元Eylea生物类似药上市申请

环球市场播报06-05

冰岛生物制药公司Alvotech周四宣布，已再次向美国食品药品监督管理局(FDA)提交两款生物类似药的生物制剂许可申请，分别针对强生的Simponi和再生元的Eylea。此次提交是与合作伙伴Teva共同推进的，标志着两家公司在拓展美国生物类似药市场方面迈出关键一步。　　这两款药物分别为AVT05和AVT06。AVT05是强生旗下Simponi及其静脉注射剂型Simponi Aria的生物类似药，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2641164638?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-05 03:16","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2641164638","market":"us","top_or_hot":-1,"title":"Alvotech再次向FDA提交强生Simponi和再生元Eylea生物类似药上市申请","media":"环球市场播报","content":"<div>\n<p>冰岛生物制药公司Alvotech周四宣布，已再次向美国食品药品监督管理局(FDA)提交两款生物类似药的生物制剂许可申请，分别针对强生的Simponi和再生元的Eylea。此次提交是与合作伙伴Teva共同推进的，标志着两家公司在拓展美国生物类似药市场方面迈出关键一步。\n　　这两款药物分别为AVT05和AVT06。AVT05是强生旗下Simponi及其静脉注射剂型Simponi Aria的生物类似药，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-06-05/doc-iniahtfh8923892.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alvotech再次向FDA提交强生Simponi和再生元Eylea生物类似药上市申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlvotech再次向FDA提交强生Simponi和再生元Eylea生物类似药上市申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 03:16 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-06-05/doc-iniahtfh8923892.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>冰岛生物制药公司Alvotech周四宣布，已再次向美国食品药品监督管理局(FDA)提交两款生物类似药的生物制剂许可申请，分别针对强生的Simponi和再生元的Eylea。此次提交是与合作伙伴Teva共同推进的，标志着两家公司在拓展美国生物类似药市场方面迈出关键一步。\n　　这两款药物分别为AVT05和AVT06。AVT05是强生旗下Simponi及其静脉注射剂型Simponi Aria的生物类似药，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-06-05/doc-iniahtfh8923892.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALVO","symbol_name":"Alvotech","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-05/doc-iniahtfh8923892.shtml","article_id":"2641164638","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641164638","pubTimestamp":1780600560,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"冰岛生物制药公司Alvotech周四宣布，已再次向美国食品药品监督管理局提交两款生物类似药的生物制剂许可申请，分别针对强生的Simponi和再生元的Eylea。此次提交是与合作伙伴Teva共同推进的，标志着两家公司在拓展美国生物类似药市场方面迈出关键一步。AVT05是强生旗下Simponi及其静脉注射剂型Simponi Aria的生物类似药，该药属于肿瘤坏死因子阻滞剂，用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎、溃疡性结肠炎等多种慢性炎症性疾病。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ALVO":"Alvotech","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","BK4139":"生物科技","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU1228905037.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4592":"伊斯兰概念","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4504":"桥水持仓","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","JNJ":"强生","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4588":"碎股","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4007":"制药","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IPOS":"Renaissance International IPO ETF","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LABU":"三倍做多标普生物-Direxion","IE000F7OJYX1.SGD":"RQI GLOBAL \"I\" (SGDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","LU1121112475.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USDHDG) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC"},"translate_title":"Alvotech Again Submits Marketing Applications for Johnson & Johnson Simponi and Regeneron Eylea Biosimilars to the FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"ALVO":1.5,"LABU":1.5,"JNJ":1.5},"content_text":"冰岛生物制药公司Alvotech周四宣布，已再次向美国食品药品监督管理局(FDA)提交两款生物类似药的生物制剂许可申请，分别针对强生的Simponi和再生元的Eylea。此次提交是与合作伙伴Teva共同推进的，标志着两家公司在拓展美国生物类似药市场方面迈出关键一步。\n　　这两款药物分别为AVT05和AVT06。AVT05是强生旗下Simponi及其静脉注射剂型Simponi Aria的生物类似药，该药属于肿瘤坏死因子阻滞剂，用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎、溃疡性结肠炎等多种慢性炎症性疾病。AVT06则是再生元Eylea的生物类似药，Eylea是血管内皮生长因子抑制剂，用于治疗新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿及视网膜静脉阻塞等可能导致视力丧失或失明的视网膜疾病。\n　　此次重新提交源于FDA此前对Alvotech位于雷克雅未克的生产设施发出的完整回应函。FDA在2025年对该设施的检查中提出了三项主要观察意见，涉及硅润滑剂使用、投诉处理流程及微生物污染问题。Alvotech已完成整改并收集了约六个月的可持续改进数据。公司于2026年5月完成了FDA对该设施的GMP监督检查，预计FDA将按照常规审评时间表在六个月内完成审评。\n　　此前的临床试验数据显示，AVT05在治疗中度至重度类风湿关节炎患者的三期研究中达到了主要疗效终点，第16周的DAS28-CRP评分变化处于预设等效区间内，安全性和免疫原性与原研药相当。AVT06在治疗新生血管性年龄相关性黄斑变性患者的三期研究中也显示出与Eylea相当的疗效，最佳矫正视力变化在预设等效范围内，安全性和药代动力学特征相似。\n　　Alvotech首席战略官Balaji Prasad表示，Simponi是该产品管线中最具时间敏感性的机会，市场竞争有限，公司希望成为首批进入市场的企业之一。对于Eylea，由于相关和解协议允许在第四季度上市，时间影响相对有限。若此次申请顺利获批，两款产品均有望于年底前在美国市场推出。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641164638","isCrawlerRequest":true}